Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.40 Analyst target: $10.00 Upside: 614.29%
Pulmatrix, Inc., a clinical-stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company is headquartered in Lexington, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.